Cardiff Oncology, Inc.
NASDAQ:CRDF · NASDAQ Capital Market
-$0.05 today
Vol 1.70M · Avg 1.01M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-101.0%
avg -119.3%
ROIC
-105.9%
avg -94.3%
ROA
-74.1%
avg -73.6%
Analysis
ROA is currently the strongest return metric at -74.1% versus its period average of -73.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Tod Smeal | Chief Scientific Officer | $2.69M | — | 61 | $1.28M | 1.87% |
Josh Muntner | Chief Financial Officer | $674,750.00 | — | 57 | $487,150.00 | 0.71% |
Roger Sidhu | Chief Medical Officer | $553,000.00 | — | 50 | $0.00 | <0.01% |
Mani Mohindru | President, CEO & Director | $77,000.00 | — | 54 | $968,766.00 | 1.42% |
Brigitte Lindsay | Chief Accounting Officer | — | — | 57 | $1.03M | 1.50% |
Ajay Aggarwal | Chief Operating Officer | — | — | — | $400,000.00 | 0.59% |
Elizabeth Anderson | Vice President of Finance & Administration | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$710,500.00
Sells
0
$0.00
Net Sentiment
+$710,500.00
Net buying
Most Active
PACE GARY W
2 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| Jul 30, 2025 | PACE GARY W Indirect | Buy | 15.0K | $2.45 | $36,750.00 | |
| Jul 30, 2025 | PACE GARY W Direct | Buy | 275.0K | $2.45 | $673,750.00 |
Analysis
Insiders reported 2 buys worth $710,500.00 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $710,500.00. PACE GARY W was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | -11.4% | +58.3% (15yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at -11.4% over three years. Forward estimates point to Revenue at +58.3% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Elicio Therapeutics, Inc.
NASDAQ:ELTX
$283.43M
Forte Biosciences, Inc.
NASDAQ:FBRX
$243.83M
Innate Pharma S.A.
NASDAQ:IPHA
$165.27M
Molecular Partners AG
NASDAQ:MOLN
$154.17M
Milestone Pharmaceuticals Inc.
NASDAQ:MIST
$109.08M
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP
$102.67M
PepGen Inc.
NASDAQ:PEPG
$101.68M
Cassava Sciences, Inc.
SAVA
$63.77M
Rani Therapeutics Holdings, Inc.
NASDAQ:RANI
$49.65M
Applied Therapeutics, Inc.
APLT
$14.86M
Who manages CRDF?
Cardiff Oncology, Inc. (CRDF) lists 7 active executives. The top listed executive is Josh Muntner, Chief Financial Officer.
Are CRDF insiders buying or selling?
Recent insider activity shows net buying of $32.98M.
Explore More
Continue the stock analysis
Jump to another research area for this company.